Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.
about
Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.Profiling the Mismatch Tolerance of Argonaute 2 through Deep Sequencing of Sliced Polymorphic Viral RNAs.The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis.RNAi targeting STMN alleviates the resistance to taxol and collectively contributes to down regulate the malignancy of NSCLC cells in vitro and in vivo.
P2860
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.
@ast
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.
@en
type
label
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.
@ast
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.
@en
prefLabel
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.
@ast
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.
@en
P2093
P2860
P356
P1433
P1476
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.
@en
P2093
Christopher M Jay
Cynthia Bedell
Donald D Rao
Francis Charles Brunicardi
Gladice Wallraven
John Nemunaitis
Minal Barve
Neil Senzer
Padmasini Kumar
Robert G Mennel
P2860
P304
P356
10.1038/MT.2015.14
P577
2015-01-26T00:00:00Z